Breast cancer (B.C.) still has increasing incidences and mortality rates globally. It is known that B.C. and other cancers have a very high rate of genetic heterogeneity and genomic mutations. Traditional oncology approaches have not been able to provide a lasting solution. Targeted therapeutics have been instrumental in handling the complexity and resistance associated with B.C. However, the progress of genomic technology has transformed our understanding of the genetic landscape of breast cancer, opening new avenues for improved anti-cancer therapeutics. Genomics is critical in developing tailored therapeutics and identifying patients most benefit from these treatments. The next generation of breast cancer clinical trials has incorporated next-generation sequencing technologies into the process, and we have seen benefits. These innovations have led to the approval of better-targeted therapies for patients with breast cancer. Genomics has a role to play in clinical trials, including genomic tests that have been approved, patient selection and prediction of therapeutic response. Multiple clinical trials in breast cancer have been done and are still ongoing, which have applied genomics technology. Precision medicine can be achieved in breast cancer therapy with increased efforts and advanced genomic studies in this domain. Genomics studies assist with patient outcomes improvement and oncology advancement by providing a deeper understanding of the biology behind breast cancer. This article will examine the present state of genomics in breast cancer clinical trials.

中文翻译：

---

乳腺癌临床试验中的基因组学


全球乳腺癌（BC）的发病率和死亡率仍在上升。众所周知，乳腺癌和其他癌症具有非常高的遗传异质性和基因组突变率。传统的肿瘤学方法无法提供持久的解决方案。靶向治疗在解决乳腺癌相关的复杂性和耐药性方面发挥了重要作用。然而，基因组技术的进步改变了我们对乳腺癌遗传景观的理解，为改进抗癌治疗开辟了新途径。基因组学对于开发定制疗法和确定从这些治疗中最受益的患者至关重要。下一代乳腺癌临床试验已将下一代测序技术纳入该过程，我们已经看到了好处。这些创新使得针对乳腺癌患者的更有针对性的治疗方法获得批准。基因组学在临床试验中发挥着重要作用，包括已批准的基因组测试、患者选择和治疗反应预测。多项针对乳腺癌的临床试验已经完成并且仍在进行中，这些试验应用了基因组学技术。通过加大该领域的努力和先进的基因组研究，可以在乳腺癌治疗中实现精准医学。基因组学研究通过提供对乳腺癌背后的生物学的更深入的了解，有助于改善患者的治疗结果和肿瘤学的进步。本文将探讨乳腺癌临床试验中基因组学的现状。